The Centers for Medicare & Medicaid Services and the Office of the National Coordinator for Health Information Technology recently announced the availability of registration for Medicare and Medicaid electronic health record incentive programs.
The Centers for Medicare & Medicaid Services and the Office of the National Coordinator for Health Information Technology recently announced the availability of registration for Medicare and Medicaid electronic health record incentive programs.
As of Jan. 3, 2011, registration became available for eligible health care professionals and eligible hospitals that wish to participate in the Medicare EHR incentive program. Registration is also available for the Medicaid EHR incentive program in Alaska, Iowa, Kentucky, Louisiana, Oklahoma, Michigan, Mississippi, North Carolina, South Carolina, Tennessee, and Texas. In February, registration will open in California, Missouri, and North Dakota.
"With the start of registration, these landmark programs get under way, and patients, providers, and the nation can begin to enjoy the benefits of widespread adoption of electronic health records," said CMS Administrator Donald Berwick, MD. “CMS has many resources available to help providers register and participate, and we look forward to working with eligible professionals and eligible hospitals to facilitate the process.”
Eligible professionals and eligible hospitals must register at a registration site maintained by CMS in order to participate in the Medicare and Medicaid EHR incentive programs. To prepare for registration, interested providers are urged to first visit CMS’S official site for EHR incentive programs,http://www.cms.gov/ehrincentiveprograms.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.